España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Relmada Therapeutics
RLMD
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.3614
-0.02
-4.79%
At close: -
$0.3582
-0.00320
-0.89%
After Hours: 4:05 PM EDT
Get Report
Comment
Relmada Therapeutics (RLMD) Forecast
News
Earnings
Relmada Therapeutics (RLMD) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Relmada Therapeutics (NASDAQ:RLMD) Stock
Relmada Therapeutics Stock (NASDAQ: RLMD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, December 09, 2024
Relmada Therapeutics Announced That In Light ...
Benzinga Newsdesk
Trading Halt: Halted at 7:25:00 a.m. ET - Tra...
Benzinga Newsdesk
Thursday, December 05, 2024
Mizuho Downgrades Relmada Therapeutics to Neu...
Benzinga Newsdesk
Wednesday, December 04, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why
Vandana Singh
Nasdaq Surges 150 Points; ISM Services PMI Falls In November
Avi Kapoor
Dow Gains 250 Points; Salesforce Shares Jump After Q3 Results
Avi Kapoor
Relmada Therapeutics shares are trading lower...
Benzinga Newsdesk
Trading Halt: Halt status updated at 7:55:00 ...
Benzinga Newsdesk
Relmada Therapeutics Announced That The Pre-p...
Benzinga Newsdesk
Trading Halt: Halted at 7:25:00 a.m. ET - Tra...
Benzinga Newsdesk
Thursday, November 14, 2024
Relmada Therapeutics Initiates Dosing In Phas...
Benzinga Newsdesk
Thursday, November 07, 2024
Relmada Therapeutics Q3 2024 GAAP EPS $(0.72)...
Benzinga Newsdesk
Wednesday, November 06, 2024
A Look Ahead: Relmada Therapeutics's Earnings Forecast
Benzinga Insights
Tuesday, September 17, 2024
Relmada Therapeutics shares are trading highe...
Benzinga Newsdesk
Jefferies Upgrades Relmada Therapeutics to Bu...
Benzinga Newsdesk
Friday, August 30, 2024
Relmada Therapeutics Files For Mixed Shelf Of...
Benzinga Newsdesk
Thursday, August 08, 2024
Relmada Therapeutics shares are trading lower...
Benzinga Newsdesk
Wednesday, August 07, 2024
Relmada Therapeutics Q2 2024 GAAP EPS $(0.59)...
Benzinga Newsdesk
Wednesday, July 10, 2024
CORRECTION: (Reported June 18, 2024) Relmada ...
Benzinga Newsdesk
Wednesday, June 05, 2024
Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Avi Kapoor
Goldman Sachs Downgrades Relmada Therapeutics...
Benzinga Newsdesk
Wednesday, May 08, 2024
Relmada Therapeutics Q1 2024 GAAP EPS $(0.72)...
Benzinga Newsdesk
Tuesday, March 19, 2024
Relmada Therapeutics Q4 EPS $(0.84) Misses $(0.83) Estimate
Happy Mohamed
Recap: Relmada Therapeutics Q4 Earnings
Benzinga Insights
Relmada Therapeutics 2023 EPS $(3.28)
Benzinga Newsdesk
Earnings Scheduled For March 19, 2024
Benzinga Insights
Monday, March 18, 2024
Earnings Outlook For Relmada Therapeutics
Benzinga Insights
Thursday, February 01, 2024
Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying
Avi Kapoor
Wednesday, January 31, 2024
Relmada Therapeutics CEO Sergio Traversa Repo...
Charles Gross
Thursday, January 04, 2024
Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Relmada Therapeutics Provides Corporate Updat...
Benzinga Newsdesk
Wednesday, November 08, 2023
Relmada Therapeutics Q3 EPS $(0.73) Beats $(0...
Benzinga Newsdesk
Earnings Scheduled For November 8, 2023
Benzinga Insights
Tuesday, November 07, 2023
Earnings Outlook For Relmada Therapeutics
Benzinga Insights
Wednesday, October 11, 2023
Relmada Therapeutics To Present New Preclinic...
Benzinga Newsdesk
Friday, October 06, 2023
Relmada Therapeutics To Present Data From Its...
Benzinga Newsdesk
Thursday, September 21, 2023
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
Wednesday, September 20, 2023
Relmada Therapeutics' Lead Candidate Shows Promise In Pivotal Depression Study
Vandana Singh
Relmada Therapeutics Announces Efficacy And S...
Benzinga Newsdesk
Wednesday, August 23, 2023
Relmada Therapeutics Announced The Dosing Of ...
Benzinga Newsdesk
Tuesday, August 08, 2023
Relmada Therapeutics Q2 EPS $(0.84) Beats $(0...
Benzinga Newsdesk
Earnings Scheduled For August 8, 2023
Benzinga Insights
Monday, August 07, 2023
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
Vandana Singh
Thursday, June 15, 2023
Mizuho Reiterates Buy on Relmada Therapeutics...
Benzinga Newsdesk
Wednesday, May 31, 2023
Chief Financial Officer at Relmada Therapeutics Acquires Company Stock Options Worth 317,643 Shares
Benzinga Insights
Relmada Therapeutics Chief Executive Officer Awarded $1.53M Worth of Stock Options
Benzinga Insights
Thursday, May 11, 2023
Relmada Therapeutics: Q1 Earnings Insights
Benzinga Insights
Relmada Therapeutics Q1 EPS $(0.87) Beats $(0.89) Estimate
Happy Mohamed
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch